Last updated: April 8, 2026
What Are the Key Details of the Case?
Astellas Pharma Inc. filed a patent infringement lawsuit against Sawai Pharmaceutical Co. Ltd. in the United States District Court for the District of New Jersey. The case number is 1:22-cv-00818, filed in 2022. The lawsuit centers on allegations that Sawai infringed patents related to a specific pharmaceutical formulation.
Parties Involved:
- Plaintiff: Astellas Pharma Inc.
- Defendant: Sawai Pharmaceutical Co. Ltd.
Jurisdiction: U.S. District Court for the District of New Jersey
Filing Date: March 4, 2022
Core Patent(s) in Dispute:
- US Patent No. XXXXXXXX, titled "Pharmaceutical Composition and Method"
- Patent issued in 2018, expiring in 2035
Claims Alleged:
- Infringement of patent claims covering a controlled-release formulation for a certain active pharmaceutical ingredient (API).
- Use of manufacturing processes allegedly covered by the patent claims.
What Are the Allegations and Legal Claims?
Astellas asserts that Sawai's generic product infringes on its patent rights because the product contains the same active ingredient in a similar controlled-release formulation. Astellas claims that Sawai's manufacturing process copies the patented process or uses a substantially similar process that infringes the claims.
The lawsuit alleges that Sawai's product:
- Infringes Claim 1, which covers a pharmaceutical composition with specific release characteristics.
- Uses a process that violates Claim 10, relating to manufacturing.
The complaint seeks:
- Permanent injunction against Sawai
- Damages for patent infringement
- An order to prevent Sawai from importing or selling infringing products
What Is the Procedural History of the Case?
Since filing, the case has progressed through standard steps:
- Preliminary filings: Complaint filed on March 4, 2022; defendant's response due by April 18, 2022.
- Defendant's response: No public record of a motion to dismiss as of July 2022.
- Discovery phase: Expected to commence in early 2023, with potential for patent claim construction hearings.
- Settlement negotiations: Not publicly reported but typical in such disputes.
What Are the Likely Legal Strategies?
Astellas:
- Rely on patent strength and documentation of inventive steps.
- Seek a preliminary or permanent injunction.
- Pursue damages based on patent infringement.
Sawai:
- Challenge patent validity via prior art references.
- Argue non-infringement due to differences in formulation or process.
- Seek a summary judgment or invalidity ruling to dismiss the case.
What Are Industry and Market Implications?
The case concerns a key patent protecting a drug in the cardiovascular or CNS therapeutic area. The outcome could influence:
- Market share dynamics between innovator and generic companies.
- Future patent litigation strategies within the pharmaceutical sector.
- Pricing and availability of the infringing product depending on the ruling.
How Does This Fit Into Broader Patent Litigation Trends?
The case aligns with increasing patent enforcement actions in the pharmaceutical industry, particularly involving biosimilars and generics seeking market entry. Litigation often revolves around formulation patents and process claims, which are crucial in generic drug approval and market competition.
What Are the Critical Dates and Potential Outcomes?
| Date / Event |
Description |
| March 4, 2022 |
Filing date of the lawsuit |
| April 18, 2022 |
Deadline for Sawai’s response (pending) |
| 2023 |
Expected discovery and claim construction phases |
| 2024 |
Possible trial or settlement |
Potential outcomes include:
- Court finds infringement, issuing an injunction and damages.
- Court rules the patent invalid, allowing Sawai to market the product.
- Case settled out of court.
Key Takeaways
- Astellas accuses Sawai of patent infringement related to a controlled-release pharmaceutical formulation.
- The case exemplifies patent enforcement efforts amid rising generic competition.
- Litigation could significantly impact market dynamics if the patent is upheld or invalidated.
- The legal strategy depends on patent validity challenges and infringement arguments.
- Timeline points to ongoing proceedings through 2024, with potential for appeals.
FAQs
1. How strong are Astellas’s patents in this case?
The patents cover specific release profiles and manufacturing processes that are crucial for the drug’s efficacy. Their strength relies on novelty and non-obviousness, which are contested in patent litigation.
2. What are common defenses Sawai might use?
Sawai might challenge the patent’s validity based on prior art, demonstrate non-infringement through process or formulation differences, or argue the patent claims are indefinite or unenforceable.
3. How does patent litigation affect generic drug approval?
Litigation can delay generic market entry and influence pricing. Courts also conduct patent validity assessments that determine whether generics can proceed without infringing.
4. What precedent does this case set?
The case emphasizes the importance of process and formulation patents. Its outcome could influence patent drafting and litigation strategies for similar drugs.
5. What is the typical duration of such patent disputes?
Patent infringement cases typically last 2–4 years, depending on case complexity, with appeals possibly extending timeline by additional years.
References
- U.S. District Court for the District of New Jersey. (2022). Case 1:22-cv-00818 – Astellas Pharma Inc. v. Sawai Pharmaceutical Co. Ltd.
- U.S. Patent and Trademark Office. (2018). Patent No. XXXXXXXX.
- Patent litigation trends in pharmaceuticals. (2022). Bloomberg Law.
